- Home
- INBX vs PROK Comparison
INBX vs PROK Comparison
Compare INBX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- PROK
- Stock Information
- Founded
- INBX 2010
- PROK 2015
- Country
- INBX United States
- PROK United States
- Employees
- INBX N/A
- PROK N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INBX Health Care
- PROK Health Care
- Exchange
- INBX Nasdaq
- PROK Nasdaq
- Market Cap
- INBX 222.5M
- PROK 220.6M
- IPO Year
- INBX 2020
- PROK N/A
- Fundamental
- Price
- INBX $13.98
- PROK $1.74
- Analyst Decision
- INBX Hold
- PROK Buy
- Analyst Count
- INBX 1
- PROK 5
- Target Price
- INBX N/A
- PROK $4.50
- AVG Volume (30 Days)
- INBX 70.4K
- PROK 431.7K
- Earning Date
- INBX 11-14-2024
- PROK 11-12-2024
- Dividend Yield
- INBX N/A
- PROK N/A
- EPS Growth
- INBX N/A
- PROK N/A
- EPS
- INBX 119.38
- PROK N/A
- Revenue
- INBX $1,568,000.00
- PROK N/A
- Revenue This Year
- INBX N/A
- PROK N/A
- Revenue Next Year
- INBX N/A
- PROK N/A
- P/E Ratio
- INBX $0.12
- PROK N/A
- Revenue Growth
- INBX 19.24
- PROK N/A
- 52 Week Low
- INBX $10.80
- PROK $1.18
- 52 Week High
- INBX $18.95
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- INBX 37.51
- PROK 46.63
- Support Level
- INBX $13.27
- PROK $1.50
- Resistance Level
- INBX $14.49
- PROK $1.81
- Average True Range (ATR)
- INBX 1.00
- PROK 0.20
- MACD
- INBX -0.23
- PROK -0.01
- Stochastic Oscillator
- INBX 33.53
- PROK 32.26
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.